As Tad 600mg is administered via intravenous injection, it directly enters the bloodstream, providing optimal effectiveness
Overall, studies have shown that these medications have an established safety profile in T1D, with only a modest effect on HbA1c, but significant weight loss, and a reduction in TDI
With obesity, diabetes, cardiovascular disease, liver disease, and possibly neurodegenerative disease all becoming viable markets, the total addressable market is likely to reach or exceed USD 100-150 billion globally (perhaps more depending on healthcare policy)
Most patients with BMI 40 will likely choose retatrutide for its superior results, while those with BMI 30-40 may prefer CagriSema's faster availability
, & Shaham, Y